Ross P V, Koenig R J, Arscott P, Ludgate M, Waier M, Nelson C C, Kaplan M M, Baker J R
Department of Medicine, University of Michigan Medical School, Ann Arbor 48109-0666.
J Clin Endocrinol Metab. 1993 Aug;77(2):433-8. doi: 10.1210/jcem.77.2.8345048.
A recent report has identified a new autoantigen called D1 that appears to be associated with Graves' ophthalmopathy and is expressed in the thyroid and eye muscle. To better characterize the tissue specificity and disease relevance of this antigen, we evaluated the expression of D1 RNA in various human tissues using a reverse transcriptase polymerase chain reaction assay. These studies indicate a wide tissue distribution of the messenger RNA for this antigen, including the thyroid, eye muscle, parathyroid, spleen, skeletal muscle, and uterus. There were variations in the relative amounts of specific message for D1 in the different tissues, with the uterus, thyroid, and eye muscle having the greatest amount of product per microgram of total RNA. A maltose binding protein-D1 fusion protein was expressed in Escherichia coli, purified, and used to assess serologic reactivity to D1 by Western blot. Autoantibodies to this antigen were noted in 19 of 24 (78%) of Hashimoto's disease patients, 26 of 41 (63%) of Graves' disease patients, and in 9 of 17 (53%) of normal controls. Sixty percent of Graves' disease patients with clinical ophthalmopathy had antibodies to D1, as did 63% of Graves' patients without signs or symptoms of clinical ophthalmopathy. There was no correlation between reactivity to D1 and either clinical measures of hyperthyroidism or antibody titers to thyroid peroxidase or thyroglobulin. The presence of autoantibodies to this antigen in patients with Hashimoto's disease, in Graves' disease patients without ophthalmopathy and in normal controls indicate that serologic recognition of this antigen is not restricted to patients with ophthalmopathy. In addition, the expression of messenger RNA for this antigen in multiple types of cells questions the tissue specificity of this autoantigen.
最近的一份报告鉴定出一种名为D1的新自身抗原,它似乎与格雷夫斯眼病相关,且在甲状腺和眼肌中表达。为了更好地表征该抗原的组织特异性和疾病相关性,我们使用逆转录酶聚合酶链反应分析法评估了D1 RNA在各种人体组织中的表达。这些研究表明该抗原的信使RNA在多种组织中广泛分布,包括甲状腺、眼肌、甲状旁腺、脾脏、骨骼肌和子宫。不同组织中D1特异性信使的相对含量存在差异,每微克总RNA中,子宫、甲状腺和眼肌产生的产物量最多。一种麦芽糖结合蛋白-D1融合蛋白在大肠杆菌中表达、纯化,并用蛋白质印迹法评估其对D1的血清学反应性。在24例桥本氏病患者中有19例(78%)、41例格雷夫斯病患者中有26例(63%)以及17例正常对照中有9例(53%)检测到针对该抗原的自身抗体。60%有临床眼病的格雷夫斯病患者有抗D1抗体,无临床眼病体征或症状的格雷夫斯病患者中这一比例为63%。对D1的反应性与甲状腺功能亢进的临床指标或甲状腺过氧化物酶或甲状腺球蛋白的抗体滴度之间均无相关性。桥本氏病患者、无眼病的格雷夫斯病患者以及正常对照中存在针对该抗原的自身抗体,这表明对该抗原的血清学识别并不局限于眼病患者。此外,该抗原的信使RNA在多种类型细胞中的表达对这种自身抗原的组织特异性提出了质疑。